Evaluation of the Live Biotherapeutic Product, Asymptomatic Bacteriuria Escherichia coli 2‐12, in Healthy Dogs and Dogs with Clinical Recurrent UTI

BACKGROUND: Antimicrobial resistance is an emerging problem. HYPOTHESIS/OBJECTIVE: To investigate the safety and efficacy of a live biotherapeutic product, ASB E. coli 2‐12 for UTI treatment. ANIMALS: Six healthy research dogs; nine client‐owned dogs with recurrent UTI. METHODS: Prospective noncontr...

Descripción completa

Detalles Bibliográficos
Autores principales: Segev, G., Sykes, J.E., Klumpp, D.J., Schaeffer, A.J., Antaki, E.M., Byrne, B.A., Yaggie, R.E., Westropp, J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787194/
https://www.ncbi.nlm.nih.gov/pubmed/29243301
http://dx.doi.org/10.1111/jvim.14851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787194/
https://www.ncbi.nlm.nih.gov/pubmed/29243301
http://dx.doi.org/10.1111/jvim.14851

Ejemplares similares